Skip to main content

$0.028 -0.001 (-3.45%)

High

$0.03

Low

$0.03

Trades

20

Turnover

$17,485

Volume

622,600
30 June 2023 at 4:10pm
Register to track NYR and receive email alerts.
Subject
NYR Ann: Cholesterol-Lowering Program Update

NYR Ann: Brain Injury Program Preclinical Development Update

NYR Ann: Cholesterol-Lowering Program Preclinical Studies Completed

NYR Ann: Quarterly Activities Report and Appendix 4C

NYR Ann: Cholesterol-Lowering Program Preclinical Development Update

NYR Ann: Nyrada Half Year Results FY2023

NYR Ann: Appendix 4D and Half Year Report to 31 December 2022

NYR Ann: Quarterly Activities Report and Appendix 4C

NYR Ann: Collaboration with Walter Reed and UNSW Extended to 2025

NYR Ann: Notification of cessation of securities - NYR

NYR Ann: Brain Injury Program Update

NYR Ann: Results of Meeting

NYR Ann: AGM Presentation by James Bonnar CEO

NYR Ann: Nyrada AGM 2022 Chairmans Address

NYR Ann: Nyrada Receives A$1.2M R&D Tax Incentive Rebate

NYR Ann: CEO Remuneration Update

NYR Ann: Quarterly Activities Report and Appendix 4C

NYR Ann: 2022 AGM Letter to Shareholders and Proxy

NYR Ann: 2022 AGM Notice of Meeting and Proxy

NYR Ann: Efficacy Study Published in Journal of Lipid Research

NYR Ann: Presentation to ShareCafe Hidden Gems Webinar

NYR Ann: Presentation to E&P Small Caps Health Care Conference

NYR Ann: Nyrada Reports Full Year FY2022 Results

NYR Ann: Annual Report to June 30 2022

NYR Ann: Preliminary Final Report

NYR Ann: Appendix 4G and Corporate Governance Statement

NYR Ann: Nyrada Board Changes

NYR Ann: Initial Director's Interest Notice - GM

NYR Ann: Final Director's Interest Notice - PM

NYR Ann: Quarterly Activities Report and Appendix 4C

NYR Ann: Nyrada PCSK9 Inhibitor Tested in Model of Atherosclerosis

NYR Ann: Cholesterol-Lowering Program Update

NYR Ann: Corporate Presentation

NYR Ann: Brain Injury Program Target Unveiled and Phase I Update

NYR Ann: European Patent to be Granted for Cholesterol-Lowering Drug

NYR Ann: Nyrada Quarterly Activities Report & Appendix 4C

NYR Ann: Investor Roadshow Presentation

NYR Ann: New Drug Offers Potential Oral Treatment for Concussion

NYR Ann: Presentation to Meet the CEO Life Sciences Edition

NYR Ann: Nyrada Half Year Results FY2022

NYR Ann: Appendix 4D and Half Year Report to 31 December 2021

NYR Ann: Nyrada Quarterly Activities Report & Appendix 4C

NYR Ann: Application for quotation of securities - NYR

NYR Ann: Change of Director's Interest Notice - ID

NYR Ann: Change of Director's Interest Notice - MF

NYR Ann: Change of Director's Interest Notice - RW

NYR Ann: Change of Director's Interest Notice - JM

NYR Ann: Change of Director's Interest Notice - CC

NYR Ann: Change of Director's Interest Notice - PM

NYR Ann: Nyrada Receives A$1.3M R&D Tax Incentive Rebate

Register to track NYR and receive email alerts.

Similar Companies

CAN
CPH
EOF
IHL
MVP
MYX
NEU
PBP
RCE
SPL